“Alzheimer’s drug spurs hope”

“Alzheimer’s drug spurs hope” is the headline in today’s (6-1-15) SF Chronicle. Biogen announced a new antibody that substantially reduced abnormal protein deposits in the brain. Patients who received the therapy had significantly less cognitive decline than the control group showed. Although this clinical trial was small, a larger one is planned for July. One critical difference in the success of this new antibody compared to previous drugs that had failed is that patients were screened and treated before symptoms became pronounced. Early prevention when treatment is most effective clearly is the key.